INFO60
SpotlightTopics60sNEWQuizLogin
IndiaAI & TechBusinessTechnologySportsEntertainmentHealthScienceWorld
INFO60

Know more. Read less. What matters, fast.

Company

  • About
  • Contact
  • Editorial Policy
  • Corrections
  • Our desks
  • Publishers

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Account

  • Delete Account
  • Spotlight
  • Quick Cards
  • Topics
  • Web Stories
  • Hindi News

Free. One email a day. Unsubscribe anytime.

Editions

  • India
  • United States
  • United Kingdom
  • Canada
  • Australia
  • UAE & Gulf
  • Singapore
  • Hindi
  • All countries
© 2026 Info60. All rights reserved.
Home›business›Antengene Doses First Patient In Pivotal Phase III ATG-022 Gastric Cancer Trial; Stock Up
business

Antengene Doses First Patient In Pivotal Phase III ATG-022 Gastric Cancer Trial; Stock Up

By Info60 World Desk•Summary of reporting by Rttnews•Sep 21, 2026•0 views•
Antengene Doses First Patient In Pivotal Phase III ATG-022 Gastric Cancer Trial; Stock Up
Antengene Corporation Ltd. (6996.HK), a commercial-stage biotech company, announced Monday that the first patient has been dosed in China in the pivotal Phase III CLINCH-3 study evaluating ATG-022, a CLDN18.
ONLY AVAILABLE IN PAID PLANS
Read Full Article

Share this story

Report an error

Up next

Related Stories

US stocks: S&P 500 ends nearly flat as US-Iran talks help stocks pare losses

US stocks: S&P 500 ends nearly flat as US-Iran talks help stocks pare losses

economictimes.indiatimes.com

McDonald’s offers US$8.5 billion to help owners with overhaul

McDonald’s offers US$8.5 billion to help owners with overhaul

financialpost.com

Carney tells NYT he looked at ‘extreme tail risk’ of U.S. invasion

Carney tells NYT he looked at ‘extreme tail risk’ of U.S. invasion

financialpost.com

Former VC Partner Hsin-Ju Chuang Dies at 37: What We Know So far

Former VC Partner Hsin-Ju Chuang Dies at 37: What We Know So far

Cryptonews

Form 8.5 (EPT/RI)-Pollen Street Group Limited

Globenewswire_fr

Comments (0)

Please login to comment

Login
💬

No comments yet. Be the first to comment!